Cangrelor

Chemical formula: C₁₇H₂₅Cl₂F₃N₅O₁₂P₃S₂  Molecular mass: 776.35 g/mol  PubChem compound: 9854012

Therapeutic indications

Cangrelor is indicated for:

Coronary artery disease undergoing percutaneous coronary intervention (PCI)

Population group: only adults (18 years old or older)

Cangrelor, co-administered with acetylsalicylic acid (ASA), is indicated for the reduction of thrombotic cardiovascular events in adult patients with coronary artery disease undergoing percutaneous coronary intervention (PCI) who have not received an oral P2Y12 inhibitor prior to the PCI procedure and in whom oral therapy with P2Y12 inhibitors is not feasible or desirable.

For this indication, competent medicine agencies globally authorize below treatments (click for details):

Contraindications

Cangrelor is contraindicated in the following cases:

Stroke, transient ischaemic attack (TIA)

at least one of
CVA - Cerebrovascular accident
H/O: CVA
Temporary cerebral vascular dysfunction
History of transient ischemic attack

Bleeding, increased risk of bleeding

at least one of
Bleeding
High risk of hemorrhage

Get recommendations

Factors such as age, gender, and health history are evaluated to create a personalized medication regimen.

Ask the Reasoner

Related medicines

Summary of Product Characteristics (SPC) 2020: KENGREXAL Powder for concentrate solution
< Previous: Overview
Next: Precautions >

© All content on this website, including data entry, data processing, decision support tools, "RxReasoner" logo and graphics, is the intellectual property of RxReasoner and is protected by copyright laws. Unauthorized reproduction or distribution of any part of this content without explicit written permission from RxReasoner is strictly prohibited. Any third-party content used on this site is acknowledged and utilized under fair use principles.

⇈